Thomas Justin Tull

Thomas Justin Tull

Auto-generated profile, based on publicly available information

Thomas Justin Tull

St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust , London

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Science Immunology
Verified
Journal Article
Closed access
JSJacqueline H.Y. Siu
Jacqueline H.Y. Siu
MPMichael J. Pitcher
Michael J. Pitcher
TTThomas J. Tull
Thomas J. Tull
RVRebekah L. Velounias
Rebekah L. Velounias
WGWilliam Guesdon
William Guesdon
JSJo Spencer
Jo Spencer
B cells generate antibodies that are essential for immune protection, but their subgroups are poorly defined. Here, we perform undirected deep profiling of B cells in matched human lymphoid tissues from deceased transplant organ donors and blood. In addition to identifying unanticipated features of tissue-based B cell differentiation, we resolve two subsets of marginal zone B (MZB) cells differing in cell surface and transcriptomic profiles, clonal relationships to other subsets, enrichment of genes in the NOTCH pathway, distribution bias within splenic marginal zone microenvironment, and immunoglobulin repertoire diversity and hypermutation frequency. Each subset is present in spleen, gut-associated lymphoid tissue, mesenteric lymph nodes, and blood. MZB cells and the lineage from which they are derived are depleted in lupus nephritis. Here, we show that this depletion is of only one MZB subset. The other remains unchanged as a proportion of total B cells compared with health. Thus, it is important to factor MZB cell heterogeneity into studies of human B cell responses and pathology.

5 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TTThomas J. Tull
Thomas J. Tull
MPMichael J. Pitcher
Michael J. Pitcher
WGWilliam Guesdon
William Guesdon
JSJacqueline H.Y. Siu
Jacqueline H.Y. Siu
CLCristina Lebrero-Fernández
Cristina Lebrero-Fernández
JSJo Spencer
Jo Spencer
B cells emerge from the bone marrow as transitional (TS) B cells that differentiate through T1, T2, and T3 stages to become naive B cells. We have identified a bifurcation of human B cell maturation from the T1 stage forming IgMhi and IgMlo developmental trajectories. IgMhi T2 cells have higher expression of α4β7 integrin and lower expression of IL-4 receptor (IL4R) compared with the IgMlo branch and are selectively recruited into gut-associated lymphoid tissue. IgMhi T2 cells also share transcriptomic features with marginal zone B cells (MZBs). Lineage progression from T1 cells to MZBs via an IgMhi trajectory is identified by pseudotime analysis of scRNA-sequencing data. Reduced frequency of IgMhi gut-homing T2 cells is observed in severe SLE and is associated with reduction of MZBs and their putative IgMhi precursors. The collapse of the gut-associated MZB maturational axis in severe SLE affirms its existence in health.

1 December 2022 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
RVRebekah L Velounias
Rebekah L Velounias
TTThomas J Tull
Thomas J Tull
Summary: Our understanding of the B-cell subsets found in human blood and their functional significance has advanced greatly in the past decade. This has been aided by the evolution of high dimensional phenotypic tools such as mass cytometry and single-cell RNA sequencing which have revealed heterogeneity in populations that were previously considered homogenous. Despite this, there is still uncertainty and variation between studies as to how B-cell subsets are identified and named. This review will focus on the most commonly encountered subsets of B cells in human blood and will describe gating strategies for their identification by flow and mass cytometry. Important changes to population frequencies and function in common inflammatory and autoimmune diseases will also be described.

6 March 2025 in Allergy
Verified
Journal Article
Open access
CSChara Stavraka
Chara Stavraka
JCJitesh Chauhan
Jitesh Chauhan
SCSilvia Crescioli
Silvia Crescioli
SMSheila M. McSweeney
Sheila M. McSweeney
APAmy Pope
Amy Pope
Sophia N KaragiannisSophia N Karagiannis
Sophia N Karagiannis
Background: IgE antibodies directed against cancer antigens have demonstrated potent anti‐tumour effects in pre‐clinical studies. MOv18 IgE, the first‐in‐class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE‐treated patients. Methods: Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno‐mass spectrometry. We conducted transcriptomic analyses in paired lesional and non‐lesional skin biopsies from a patient who developed an urticarial skin reaction. Systemic immunological markers including cytokines, β‐tryptase and basophil activation states were interrogated throughout the trial and contemporaneously with the skin reaction. Results: Of the 24 IgE‐treated patients, 62.5% developed transient urticarial skin reactions, with onset during the first infusion, diminishing with consecutive infusions and no β‐tryptase elevation nor clinical features indicating allergic aetiology. No FRα expression or MOv18 IgE binding to human skin was identified. Lesional skin biopsies from a patient given the highest antibody dose revealed scattered eosinophils, neutrophils and mast cell degranulation, but no increased immune cell infiltration. Transcriptomic analysis indicated pro‐inflammatory, but not allergic, pathway activation. No systemic allergic or hypersensitivity mediators or basophil activation were detected. Conclusions: Urticarial skin reactions following MOv18 IgE treatment were unlikely to result from allergic mechanisms or skin antigen recognition. The clinical presentation is consistent with infusion‐related reactions commonly observed with monoclonal antibody treatments. Trial Registration: EudraCT number: 2014‐000070‐19; ClinicalTrials.gov identifier: NCT02546921, registered 11/Sept/2015

11 December 2024 in JID Innovations
Verified
Journal Article
Open access
MKMeropi Karakioulaki
Meropi Karakioulaki
PDPatrick Dunn
Patrick Dunn
Dedee MurrellDedee Murrell
Dedee Murrell
APAimee Payne
Aimee Payne
ESEnno Schmidt
Enno Schmidt
APAikaterini Patsatsi
Aikaterini Patsatsi

1 December 2022 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
JSJo Spencer
Jo Spencer
MBMats Bemark
Mats Bemark
TTThomas J Tull
Thomas J Tull
The importance of B cells and their critical role in the maintenance of health through generation of antibody-mediated immune protection is undoubted. However, the differences between the responses of B cells with different surface phenotypes in different microanatomical sites as well as diversity in B-cell function outside antibody production are just starting to be acknowledged and resolved. This series of reviews and papers that focus on human B cells will be divided across two issues. The first part of the review series in this issue captures practical information on identifying B-cell subtypes in blood in health and inflammatory diseases as well as describing aspects of B-cell diversity depending on immunoglobulin isotype and microanatomical context. It also explores our current understanding of cytokine production by human B cells and the effect of obesity on the B-cell response. The last review in this issue will reflect on the important lessons learned from the SARS-CoV-2 pandemic; in particular the role of antigen availability and its effect on B-cell memory and antibody production.